How Much Does Tirzepatide Cost in 2026?

Brand-name tirzepatide cost: Zepbound and Mounjaro

Tirzepatide is sold under two brand names: Zepbound (FDA-approved for weight management) and Mounjaro (FDA-approved for type 2 diabetes). The molecule is identical. The pricing, coverage, and how doctors prescribe them differ — and understanding that split matters before you call your doctor or fill a prescription.

Zepbound retail cost

Without any help, Zepbound at a retail pharmacy runs roughly $1,086 a month — close to $13,000 a year. Few people pay that number. With a GoodRx coupon the range drops to about $600–$650 a month, depending on the pharmacy and dose. That's still a significant recurring expense, but it represents a common real-world price for women who are uninsured or whose insurance excludes obesity treatment.

Mounjaro retail cost

Mounjaro's retail price runs around $1,024 a month without discounts. With GoodRx the range is typically $500–$580 a month. Because Mounjaro is approved for type 2 diabetes, not weight loss, it tends to be prescribed off-label when a doctor targets weight in a non-diabetic patient — and some insurers will only cover it for a diabetes diagnosis. If you have T2D, Mounjaro through insurance is often the most affordable tirzepatide pathway available.

LillyDirect self-pay vials: the brand option that competes with compounded

In late 2024 Eli Lilly changed the competitive landscape by selling Zepbound single-dose vials directly to self-pay patients at prices that undercut the retail pharmacy by more than half. Through the LillyDirect Self Pay Journey Program, the prices are $299 a month for 2.5mg, $399 for 5mg, and $449 for 7.5mg through 15mg — all for FDA-approved medication shipped directly from the manufacturer.

That makes LillyDirect the closest brand-name tirzepatide comes to compounded pricing, and for women who want regulatory certainty without an insurance fight, it's now genuinely competitive. The critical fine print is a 45-day refill window. Miss it and the higher doses jump to roughly $499–$699 a month. Set a calendar reminder before your first delivery arrives.

• Pros: FDA-approved finished product; direct from Lilly; $299 starting dose puts it in range of compounded programs.
• Cons: 45-day refill deadline is strict — missing it triggers a significant price jump; higher maintenance doses still cost more than the cheapest compounded programs.
• To access LillyDirect pricing you must use the program through a participating telehealth provider or the LillyDirect platform — not your local pharmacy.

Compounded tirzepatide cost: $199–$449/mo through telehealth

Compounded tirzepatide from 503A pharmacies remains the lowest-cost pathway in 2026 for most cash-pay patients. Prices vary more than the landing pages suggest — the monthly bill depends on the provider's membership structure, whether they quote a starter or maintenance dose, and how they handle titration price increases. The honest all-in range across major providers is about $199 to $449 a month.

Curex — lowest verified all-in price

Curex quotes approximately $199 a month as a single all-in figure that covers medication, consult, and shipping — with no separate membership fee. That transparency earns it the top spot, though the $199 is a starter-dose number. Ask for the full dose ladder in writing before committing.

Mochi Health — flat medication fee plus membership

Mochi's medication price is a flat $199 a month at every dose — a genuine advantage during titration when other programs raise the fee with each step up. The part the homepage downplays is a separate $79 a month membership, bringing the real all-in cost to about $278. For a long titration a dose-flat fee that doesn't climb can still beat a lower-headlined rival whose per-dose cost keeps rising.

Henry Meds — oral or injectable, bundled billing

Henry Meds is one of the few providers offering tirzepatide as an oral tablet, not just an injection. Oral runs about $349 a month; injection about $449. Both include visits, supplies, and shipping in a single all-in price with no long-term contract. It is not the cheapest entry, but the oral option and the bundled simplicity are the real draw for women who want to avoid weekly injections.

Willow — $399/mo in 33 states

Willow charges approximately $399 a month all-in for compounded tirzepatide and is currently available in 33 states. The single flat price across doses keeps the math simple. Confirm your state eligibility on their site before starting the intake process.

A short note on legal footing for all of these: compounded tirzepatide is pharmacy-mixed medication, not FDA-approved as a finished product. After the tirzepatide shortage was resolved in December 2024, broad shortage-era compounding wound down. What remains is a narrow 503A individual-patient pathway requiring a documented clinical reason the approved version won't work for that specific patient. The ground is evolving — confirm with any provider exactly how they source and document compounded tirzepatide today.

Insurance coverage for tirzepatide

Insurance is the most affordable tirzepatide pathway for women who qualify — and more qualify than realize it. Zepbound is covered by many major commercial insurers for obesity treatment when a patient has a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as hypertension, high cholesterol, or sleep apnea. With coverage in place, a monthly copay of $0–$50 is common.

Mounjaro follows different coverage rules. Because it is approved for type 2 diabetes, insurers typically cover it only for patients with a T2D diagnosis. Medicare Part D notably excludes weight-loss drugs as a category, so Medicare patients are rarely covered for Zepbound unless a state Medicaid program has added it.

• Start with your insurer's formulary: look up Zepbound (tirzepatide) under the obesity/weight management benefit, not just the drug benefit.
• Ask your doctor to confirm the diagnosis codes used on the prior authorization — BMI alone usually isn't enough; a comorbidity code matters.
• Employer self-insured plans set their own coverage rules; some large employers have added GLP-1 obesity coverage in 2025–2026 where they hadn't before.
• If denied, appeal with clinical documentation — many initial denials are reversed on the first appeal with a letter from your physician.
• Lilly's Zepbound savings card may bring copays down to $25/mo for eligible commercially insured patients when coverage exists.

Annual cost math: what each pathway actually costs you per year

Monthly numbers obscure the real decision. Spreading each pathway across 12 months makes the stakes clearer.

• With insurance (copay): $0–$600/year — by far the cheapest pathway if you qualify.
• Curex compounded (~$199/mo): ~$2,388/year.
• Mochi Health all-in (~$278/mo): ~$3,336/year.
• Henry Meds oral (~$349/mo): ~$4,188/year.
• LillyDirect Zepbound vials, starter dose ($299/mo): ~$3,588/year.
• LillyDirect Zepbound vials, maintenance dose ($449/mo): ~$5,388/year.
• Zepbound retail with GoodRx (~$625/mo): ~$7,500/year.
• Zepbound retail, no discount (~$1,086/mo): ~$13,032/year.

The gap between the cheapest compounded option and unassisted retail is roughly $10,600 a year. Even the mid-tier compounded programs save $4,000–$6,000 compared to retail without coupons. And note that some providers bill every 28 days rather than monthly — that's 13 charges a year, not 12, which adds about 8% to any quoted monthly figure.

Why tirzepatide matters especially for women in perimenopause and menopause

The weight gain that often arrives in perimenopause is not the same as ordinary lifestyle weight gain. Declining estrogen shifts fat storage toward the abdomen, slows metabolic rate, and disrupts the appetite-regulating hormones leptin and insulin in ways that make previously successful strategies stop working. GLP-1 receptor agonists like tirzepatide act on GIP and GLP-1 pathways that regulate appetite signaling, gastric emptying, and insulin sensitivity — mechanisms that are often disrupted specifically by the hormonal environment of menopause.

Clinical trial data for tirzepatide (the SURMOUNT series) showed average weight loss of 15–22% of body weight over 72 weeks — results that are meaningful for managing the cardiovascular risk that rises after menopause, not just for appearance. Several obesity-medicine physicians note that GLP-1 medications can be a particularly well-matched tool during the menopausal transition, and some clinics now combine them with hormone therapy to address both the hormonal and metabolic sides simultaneously.

None of that changes the cost calculation, but it does reframe the question from 'is this worth the money for weight loss' to 'is this worth the money for metabolic health during a vulnerable transition.' For many women, that reframe matters.